Recently, it has been demonstrated that paclitaxel exhibits preferential toxicity to folliculin (FLCN)-deficient renal cell carcinoma (RCC) line, UOK257, a cell line which originated from a patient with Birt–Hogg–Dube (BHD) syndrome [10]. This evidence concerns the gene FLCN and hereditary clear cell renal cell carcinoma.